GlassScriptPhysician profile
Caroline Fitzpatrick
NPI 1508655572
$1,314.47
in general payments reported to CMS, 2019-2025
24 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $188.65 | 2025 | Darzalex, Talvey, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $129.77 | 2025 | Entyvio, Hyqvia |
| Abbvie INC. | $100.89 | 2025 | |
| Medtronic, INC. | $90.92 | 2025 | Ligasure, Rapidvac, Sonicision |
| Tersera Therapeutics LLC | $90.69 | 2025 | Xermelo, Quzyttir |
| Azurity Pharmaceuticals, INC. | $78.83 | 2025 | Danziten |
| Lundbeck LLC | $67.44 | 2025 | Vyepti |
| Pharmaessentia USA Corporation | $58.45 | 2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $55.46 | 2025 | Ultomiris |
| Sandoz INC. | $54.86 | 2025 | Jubbonti, Tyruko, Zarxio |
| Invivyd INC | $53.71 | 2025 | Pemgarda |
| Puma Biotechnology, INC. | $39.38 | 2025 | |
| Octapharma USA, INC. | $37.64 | 2025 | Octagam Immune Globulin (Human) |
| Corcept Therapeutics | $33.05 | 2025 | Korlym |
| Jazz Pharmaceuticals INC. | $32.76 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.85 | 2025 | Nucala |
| Recordati_rare_diseases_inc. | $25.30 | 2025 | Sylvant |
| Sun Pharmaceutical Industries INC. | $24.52 | 2025 | |
| Genentech USA, INC. | $22.53 | 2025 | Ocrevus Zunovo |
| Amneal Pharmaceuticals LLC | $21.88 | 2025 | Alymsys |
| Spectrum Pharmaceuticals INC. | $20.31 | 2025 | Rolvedon |
| Sobi, INC | $20.21 | 2025 | |
| Iovance Biotherapeutics, INC. | $19.43 | 2025 | Amtagvi |
| Pfizer INC. | $18.94 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.